Company intelligence / Profile preview
Memgen
Houston, Texas, United Statesmemgenbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MEM-288 demonstrated tumor shrinkage and disease control in 50% of advanced NSCLC patients with only mild and transient treatment-related side effects. The therapy showed signs of anti-tumor immune response generation, with the ability to shrink tumors and increase immune response even in stage 4 patients who had multiple prior treatments[1][5].
- Therapeutic areas
- Oncology
- Modalities
- Viral immunotherapiesCell-based immunotherapies (TILs)Infectious disease vaccine adjuvants
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Moffitt Cancer Center
Beyond the preview
Go deeper on Memgen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Memgen.